Disease management

Global Care Management Solutions Strategic Business Report 2024: Market to Reach $36.7 Billion by 2030, Cloud Solutions Accelerating Care Delivery - ResearchAndMarkets.com

Retrieved on: 
화요일, 5월 28, 2024
Data Management, Health, Technology, Health Technology, Managed Care, Software, Artificial Intelligence, Cloud, Growth, Disease management, Artificial intelligence, Pet industry

The "Care Management Solutions - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Care Management Solutions - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • Disease management is emerging as a trending segment within care management solutions, reflecting recent market activity focused on improving patient outcomes in chronic disease care.
  • Artificial intelligence (AI) is playing an increasingly crucial role in care management, particularly in chronic care management.
  • The growing awareness of the benefits of collaborative care provides a strong foundation for the increased adoption of care management solutions.

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Retrieved on: 
목요일, 2월 8, 2024
Manuscript, KRYS, Paratriathlon, Pannus, Patient, Disease management, Scar, Ophthalmology, FDA, Abrasion, Concha bullosa, DEB, Risk, Research and development, Gene, Blister, Associate, Suma, Doctor of Philosophy, NEJM, Eye, Pharmaceutical industry

PITTSBURGH, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced data on the compassionate use of beremagene geperpavec (B-VEC), administered as an eyedrop to treat a patient with dystrophic epidermolysis bullosa (DEB) with cicatrizing conjunctivitis has been published in the New England Journal of Medicine (NEJM). The full manuscript, titled “Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa,” can be found in the February 8, 2024 issue of the NEJM.

Key Points: 
  • The full manuscript, titled “Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa,” can be found in the February 8, 2024 issue of the NEJM.
  • Over 25% of patients with DEB develop ocular complications such as corneal erosions, abrasions, blistering and scarring that can lead to impaired vision.
  • The NEJM publication describes the first application of B-VEC to treat ocular complications in a patient with DEB under a compassionate use program.
  • If approved, this approach could drastically benefit these patients.”
    A patient presented with severe cicatrizing conjunctivitis secondary to DEB.

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Retrieved on: 
화요일, 6월 27, 2023
GTA MyCar, Neurotransmission, University, MuSK protein, Lancet Neurology, GMG, Pathology, Fc receptor, Acetylcholine, Disease management, Immunoglobulin G, There, Information, U.S. FDA, UCB, Protein, Patient, University of Toronto, Division, Brussels Stock Exchange, Autoimmune disease, NMJ, University Health Network, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, The Lancet, Food, Safety, Disease, Pharmaceutical industry, Vaccine, Neurology

"There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.

Key Points: 
  • "There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.
  • RYSTIGGO ® is a new treatment option, targeting one of the mechanisms of disease to provide symptom improvement in patient-and physician reported outcomes at day 43."
  • The approval of RYSTIGGO® means doctors have an additional approved treatment option for their gMG patients who have not yet found a treatment that meets their needs."
  • RYSTIGGO® is also currently under review by the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of adults with gMG.

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Retrieved on: 
목요일, 6월 1, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, Brainstem, L1, Attack, Glial fibrillary acidic protein, Serum, Disability, Spinal cord, RCP, Heinrich Heine University Düsseldorf, Philip Niarchos, Expanded Disability Status Scale, Prognosis, NMOSD, Brain, Medicine, Biomarker, Department of Neurology, Xuanwu hospital, Disease management, EDSS, Medical school, Journal, Journal of Neurology, Neurosurgery, and Psychiatry, Patient, Risk, Randomized controlled trial, Psychiatry, Optic nerve, Neurosurgery, Disease, Medical imaging

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.

Key Points: 
  • NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.
  • Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks.
  • The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability.
  • Compared with placebo, UPLIZNA was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks.

Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research

Retrieved on: 
목요일, 2월 2, 2023
Columbia University Irving Medical Center, Disease management, Research, MD Anderson Cancer Center, Genomics, KT, Chromosome, SNV, OGM, Cancer, Multiple myeloma, SVS, FISH, HRD, TNBC, Curie Institute (Paris), Fluorescence, Hospital, Poster, WGS, University, Harvard Medical School, Medical college, Genome, NGS, Laboratory, Breast, Augusta University, SAN, Quality control, Potency (pharmacology), Neoplasm, Clinical trial, T-cell lymphoma, Sheba Medical Center, Workflow, Medical College of Georgia, Whole genome sequencing, Karyotype, In situ hybridization, Doctor of Philosophy, FACMG, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Microscope, Brigham, Genentech, VIA

During this four-day online event, presenters reported on their use of OGM for applications in genetic disease, cancer and cell bioprocessing.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in genetic disease, cancer and cell bioprocessing.
  • OGM was highlighted by researchers as a high-performance, one-stop platform, potentially eliminating the need for multiple sequential testing.
  • Aside from high concordance with classical cytogenetic methods, OGM produced additional relevant findings in 52% of all analyzed samples.
  • (Day 2)
    OGM has additional potential applications, including cell bioprocessing QC, in academic and commercial laboratory settings.

Global Sustainable Agrochemicals for Crop Protection Market Analysis Report 2022: Technology Analysis, Funding and Consortia, Growth Opportunities, Intellectual Property Lens - ResearchAndMarkets.com

Retrieved on: 
목요일, 1월 19, 2023
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Climate change, Fertilizer, GHG, Pesticide, Crop protection, Disease management, Biodiversity loss, Nanotechnology, Agrochemical, Research, Food industry, Fine chemical

The "Growth Opportunities in Sustainable Agrochemicals for Crop Protection" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Sustainable Agrochemicals for Crop Protection" report has been added to ResearchAndMarkets.com's offering.
  • This research service focuses on identifying and analyzing agricultural innovation pertaining to crop protection management through sustainable agrochemicals.
  • As conventional agrochemicals contribute to greenhouse gas (GHG) emissions, technology developers are focusing on sustainable agrochemicals that promise to reduce GHG emissions.
  • Sustainable agrochemicals for crop protection: geographical and regulatory outlook and importance of sustainable agrochemicals
    Why Is It Increasingly Difficult to Grow?

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

Retrieved on: 
화요일, 1월 17, 2023
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Disease management, MSS, Conference, Patient, SEER, Registry, Pharmaceutical industry, Medical imaging

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii.
  • “At Castle, we are committed to challenging the status quo to improve disease management through deep scientific expertise, unique value insight and strong data development,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • The vast majority of excision decisions and follow-up changes were aligned with GEP results across the uncertain scenarios.
  • Overall, the study demonstrates how diagnostic GEP test results can aid clinicians in making personalized and more confident patient management decisions.

Recuro Health Appoints Managed Care and Healthcare Data Expert Josh Nordtvedt as Senior Vice President, Payer Strategy

Retrieved on: 
목요일, 1월 12, 2023
Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Managed Care, Health, General Health, Data Management, MSSP, ARRA, Acos, Star, American Recovery and Reinvestment Act of 2009, Internationalized domain name, Disease management, Health, Risk, Collection, Accountable care organization, Case management, Population health, EMR, Inovalon, Provisions of the Affordable Care Act, Data analysis, Data management, Multimedia, Risk-adjusted return on capital, Health insurance, Management, Tom Nordtvedt

Recuro Health (Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, today announces the appointment of Josh Nordtvedt as senior vice president, Payer Strategy, effectively immediately.

Key Points: 
  • Recuro Health (Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, today announces the appointment of Josh Nordtvedt as senior vice president, Payer Strategy, effectively immediately.
  • With more than 20 years’ experience in data analysis and aggregation, risk adjustment and health plan quality ratings, Nordtvedt brings deep expertise and understanding of the payer marketplace and the downstream processes that help to improve patient health.
  • “By joining the talented leadership team at Recuro, I can participate in truly executing changes to the system and further my commitment to making healthcare a human right.
  • It is an opportunity to bring about personalized and tailored services that are free of administrative burden and bias.”

The Future of Medicine Captured in New Short Documentary

Retrieved on: 
화요일, 1월 10, 2023
Face, Patient, Mindfulness, Medicine, Partnership, Life, Movement, Disease management, Health, Physician, Alternative, Pharmaceutical industry, Health insurance, MD

PHOENIX , Jan. 10, 2023 /PRNewswire/ -- Through candid conversations and personal stories from forward-thinking physicians and an inspiring patient, a new short documentary featuring Fullscript, a digital health platform that helps practitioners build better patient relationships through quality supplementation and intuitive tools for treatment adherence, explores how integrative medicine can help heal our healthcare system. The emotional film captures the unprecedented challenges our society is facing and points to a brighter future. 

Key Points: 
  • The emotional film captures the unprecedented challenges our society is facing and points to a brighter future.
  • "The biggest obstacle we face in medicine right now is that we are taught to manage disease," said Jeff Gladd, MD, a practicing integrative medicine physician and chief medical officer at Fullscript.
  • The six-minute short documentary further illustrates how integrative medicine physicians including Cheng Ruan, MD, Founder, Texas Center for Lifestyle Medicine, and Tieraona Low Dog, MD, physician, author, and educator, look beyond symptoms, address root causes, and treat the whole patient.
  • "Fullscript is inspired to lead integrative medicine into being the healthcare of the future because patients deserve better," Gladd added.

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

Retrieved on: 
목요일, 1월 5, 2023
Immunosuppression, Eosinophilic esophagitis, Allergy, LOS, Patient, Safety, EOE, Immune system, Quality of life, Disease management, Autoimmunity, Allergen, Pharmaceutical industry

“The ability of ’1104 to reduce and reset the inflammatory immune response to common allergens has the potential to provide a long-awaited improvement to disease management with less frequent dosing without immunosuppression,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics.

Key Points: 
  • “The ability of ’1104 to reduce and reset the inflammatory immune response to common allergens has the potential to provide a long-awaited improvement to disease management with less frequent dosing without immunosuppression,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics.
  • “Having finalized enrollment and randomization of the trial, we believe we are on track to have topline data in Q2 2023.
  • A medication that provides patients with longer-term symptom relief with less dosing and no immune suppression would be a true improvement.
  • All participants receive six doses of either the investigational drug, ‘1104, or the matched placebo over six visits within a 12-week period.